Top-line and EPS Growth
Total company revenue rose 11% year-over-year to $61.0 billion in Q3; gross profit increased 18% to $2.5 billion; enterprise operating earnings grew 18% to $956 million; third quarter non-GAAP EPS was $3.17, up 35%.
Pharmaceutical & Specialty Strength
Pharma segment revenue grew 11% to $56.1 billion and segment profit increased 18% to $784 million. Specialty delivered robust growth (over 20% in Q3), GLP-1 revenue grew over 30% (adding ~6 percentage points to revenue growth), and management reiterated expectation for Specialty revenue to exceed $50 billion in fiscal 2026.
Other Growth Businesses Driving Outperformance
At-Home Solutions, Nuclear & Precision Health Solutions and OptiFreight grew revenue 31% to $1.7 billion and segment profit 34% to $179 million. Theranostics revenue grew >30%, OptiFreight revenue nearly 20%, and the ADS integration into at-Home Solutions is progressing with meaningful patient and employee onboarding.
Strong Cash Flow and Capital Allocation
Generated $1.7 billion of adjusted free cash flow in the quarter; ended the quarter with nearly $4.0 billion cash. Raised full-year adjusted free cash flow guidance to $3.3–$3.7 billion (from $3.0–$3.5B). Returned capital via share repurchases of $1.0 billion year-to-date (including an additional $250 million ASR), prepaid $100 million on term loan and reduced Moody's-adjusted leverage to ~3.0x.
Raised and Narrowed Fiscal Year Guidance
Raised full-year fiscal 2026 non-GAAP EPS guidance to $10.70–$10.80 (≈$0.50 increase at midpoint; implied annual EPS growth 30–31%). Increased Pharma segment profit growth outlook to 22–23% (from 20–22%) and raised Other growth businesses profit guidance to 36–38% (from 33–35%).
Operational Execution & Service Levels
Management highlighted record-high service levels, successful integration of recent acquisitions (e.g., ADS, onboarding of Solaris/GIA distribution volumes in Q4) and effective operational responses to winter storms and supply chain complexity.